Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle. (Q42284484)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Linda Lua

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

6

Anton P J Middelberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Melisa R Anggraeni

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yang Wu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yap P Chuan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

8 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

4428-4435

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

De novo design of catalytic proteins

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Structure-based design of conformation- and sequence-specific antibodies against amyloid β.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Recent progress in biomolecular engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Engineering allosteric protein switches by domain insertion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Production of functional chimaeric mouse/human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Structure-based antigen design: a strategy for next generation vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Challenges for the production of virus-like particles in insect cells: The case of rotavirus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Towards the preparative and large-scale precision manufacture of virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Hepatitis E vaccine development: a 14 year odyssey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Escherichia coli-based cell-free synthesis of virus-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Virus-like particles in vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Virus-like particles as vaccines and vessels for the delivery of small molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Virus-like particles: a new family of delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

A universal influenza A vaccine based on the extracellular domain of the M2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

A candidate dual vaccine against influenza and noroviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Chimeric calicivirus-like particles elicit specific immune responses in pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Emergence and pandemic potential of swine-origin H1N1 influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Mechanism of neutralization of influenza virus infectivity by antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

The predicted antigenicity of the haemagglutinin of the 1918 Spanish influenza pandemic suggests an avian origin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Protein grafting of an HIV-1-inhibiting epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Tandem repeats in proteins: from sequence to structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

High-level expression of soluble viral structural protein in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Quaternary size distribution of soluble aggregates of glutathione-S-transferase-purified viral protein as determined by asymmetrical flow field flow fractionation and dynamic light scattering.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Acceptable levels of endotoxin in vaccine formulations during preclinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Quantitative analysis of virus-like particle size and distribution by field-flow fractionation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Vaccine design of hemagglutinin glycoprotein against influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

A vaccine for HIV type 1: the antibody perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Is protein folding hierarchic? I. Local structure and peptide folding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Affinity purification of viral protein having heterogeneous quaternary structure: modeling the impact of soluble aggregates on chromatographic performance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Microbial production of virus-like particle vaccine protein at gram-per-litre levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Self-assembly of purified polyomavirus capsid protein VP1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Glycosylation of recombinant protein therapeutics: control and functional implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

N-linked oligosaccharides as outfitters for glycoprotein folding, form and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

A molecular basis for glycosylation-induced conformational switching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Effects of glycosylation on peptide conformation: a synergistic experimental and computational study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Roles of N-linked glycans in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

How N-linked oligosaccharides affect glycoprotein folding in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

UCSF Chimera--a visualization system for exploratory research and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.06.087

10.1016/J.VACCINE.2013.06.087

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23845811%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference